A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St. Michael’s Hospital of Unity Health Toronto and Harvard Medical School. Published today in JAMA Network Open, the research hones in on osimertinib, a treatment recently approved in North America as a therapy for metastatic non-small cell lung cancer with a specific mutation.
There is a lack of evidence to support the use of targeted therapy – or small molecules that target the specific drivers of a cancer – in metastatic brain disease. The researchers set out to fill this gap by further analyzing whether this targeted treatment, known for its ability to cross the blood-brain barrier, might be beneficial to patients whose lung cancer had spread to the brain.
Read more at: https://neurosciencenews.com/brain-cancer-lung-15986/